The PIPE included common stock and warrants

Davis Polk advised the placement agent in connection with Aligos Therapeutics, Inc.’s $92 million private placement of common stock, pre-funded warrants and accompanying warrants.

Aligos is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver and viral diseases. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to discover and develop potentially best in class therapeutics for nonalcoholic steatohepatitis (NASH) and viruses with high unmet medical need such as coronaviruses and chronic hepatitis B (CHB).

The Davis Polk corporate team included partner Alan F. Denenberg and associates Dana Lueck-Mammen and Eddie Magana. All members of the Davis Polk team are based in the Northern California office.